(3 hours)
All questions are to be answered. Each question to be answered in a separate book (or books if more than
one is required for the one answer).
Al die vrae moet beantwoord word. Elke vraag moet in n aparte boek (of boeke indien meer as een nodig is
vir n vraag) geskryf word.
Question1/Vraag1
a)
Describe how myocardial contraction and relaxation occurs.
(20)
b)
Discuss the factors that increase myocardial contractility.
(10)
c)
With the aid of a diagram explain the Frank-Starling law of the heart. Discuss
the proposed underlying mechanism and include the effect of inotropy and
afterload on the relationship.
(10)
d)
Draw a fully annotated normal left ventricular pressure-volume loop.
(8)
i)
Indicate on your diagram what effect an increase in preload would have
on stroke volume.
(2)
[50]
a)
b)
c)
d)
Question2/Vraag2
a)
Describe the foetal circulation.
(20)
b)
Describe the mechanisms of transition to adult circulation.
(20)
c)
A one-month-old baby presents with central and peripheral cyanosis. On
investigation the baby is shown to have a large ventricular septal defect,
pulmonary artery stenosis, an overriding aorta and right ventricular
hypertrophy.
d)
Define physiologically
i)
Central cyanosis.
(1)
ii)
Peripheral cyanosis.
(1)
PTO/Page 2 Question 2e)
-2e)
With the aid of an annotated diagram explain why the child is cyanosed.
a)
b)
c)
d)
e)
(8)
[50]
Question3/Vraag3
a)
You administer an anaesthetic an altitude of approximately 1700m, with a
barometric pressure of 630mmHg (84kPa). The arterial PCO2 is 36mmHg
(4.8 kPa)
i)
What is the difference in the inspired room air oxygen concentration
between sea-level and 1700m?
(5)
ii)
Assuming the patient is breathing room air calculate this patients
alveolar PO2 using the alveolar gas equation
(3)
iii)
Describe the physiology of the ventilatory response to increasing
altitude.
(4)
iv)
What are the beneficial and harmful physiological changes that occur
secondary to hypoxia from living at high altitude?
(6)
b)
You pre-oxygenate this healthy adult patient for surgery with 100% oxygen for
3 minutes
i)
What is the main objective of pre-oxygenation?
(1)
ii)
Based on a FRC of 30ml/kg in a 70kg male, calculate the increase in
oxygen in the lung using the alveolar gas equation at sea level. .
Assume that the FRC had an oxygen concentration of 13% prior to preoxygenation and therefore contained 270mls of oxygen.
(5)
iii)
What is an expected basal metabolic rate of oxygen consumption for
an adult and how much longer would the patient therefore tolerate
apnoea?
(3)
iv)
How is oxygen carried in the body?
(3)
v)
How much does dissolved oxygen increase in the presence of
breathing 100% oxygen?
(2)
c)
During the procedure a large volume of CO2 is insufflated into the abdominal
compartment
i)
What are the factors that determine blood flow through the lungs and
briefly describe (with appropriate diagrams) how this varies from apex
to base in a normal standing patient?
(10)
d)
What effect would abdominal CO2 insufflation have on
i)
PaCO2.
(3)
ii)
PaO2.
(3)
[50]
-3-
a)
b)
c)
d)
Question4/Vraag4
a)
List the divisions of the renal artery that supply the kidney.
(5)
b)
Describe how the arterial divisions are adapted to perform their role in
filtration and water conservation.
(15)
c)
Draw and label a juxtamedullary nephron.
(8)
d)
Briefly describe how the nephron is adapted to perform its role in
reabsorbtion and secretion.
(6)
e)
How are the nephron and collecting duct adapted to regulate water
homeostasis?
(9)
f)
What is the function of the juxtaglomerular apparatus.
(4)
g)
What anatomical and physiological adaptations allow the JGA to
function efficiently?
(3)
[50]
-44
a)
b)
c)
d)
e)
f)
g)
Lys die divisies van die renale arterie wat die nier voorsien.
(5)
Beskryf hoe die arterile divisies aangepas is om hul rol te vervul in
filtrasie en waterkonservering.
(15)
Teken en benoem n jukstaglomerulre nefron.
(8)
Beskryf kortliks hoe die nefron aangepas is vir die funksie van
herabsorpsie en sekresie.
(6)
Hoe is die nefron en versamelbuise aangepas vir waterhomeostase?
(9)
Wat is die funksie van die jukstaglomerulre apparaat?
(4)
Watter anatomiese en fisiolopgiese aanpassings laat die JGA toe om
doeltreffend te funksioneer?
(3)
[50]
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
Question 1 5 / Vraag 1 - 5
-2Question 1 / Vraag 1
a)
List the digestive enzymes secreted by the exocrine pancreas.
(2)
a)
Lys die spysverteringsensieme wat afgeskei word deur die eksokriene pankreas. (2)
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
b)
Describe the mechanisms that are responsible for preventing auto-digestion of the
pancreas.
(3)
b)
Beskryf die meganismes verantwoordelik vir die voorkoming van outo-vertering van
diepankreas.
(3)
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
c)
c)
(5)
(5)
i)
Cephalic phase.
i)
Kefaliese fase.
_________________________________________________________________________
_________________________________________________________________________
ii)
Gastric phase.
ii)
Gastriese fase
_________________________________________________________________________
_________________________________________________________________________
iii)
Intestinal phase.
iii)
Intestinale fase.
_________________________________________________________________________
_________________________________________________________________________
[10]
b)
b)
c)
c)
What are the normal values for mean pulmonary artery pressure and pulmonary
vascular resistance?
(1)
Wat is die normale waardes vir gemiddelde pulmonale arteridruk en pulmonale
vaskulre weerstand?
(1)
Discuss the effects that the following factors have on pulmonary vascular resistance
Bespreek die effekte wat die volgende faktore het op pulmonale vaskulre
weerstand
i)
i)
(2)
(2)
ii)
ii)
Lung volume.
Longvolume.
(3)
(3)
(4)
(4)
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
[10]
PP = pulse pressure
PP = polsdruk
a)
A patient is rushed back to theatre for a post-operative bleed. Explain the respiratory
variations in pulse pressure as seen in this diagram.
(6)
a)
n Pasint word teruggehaas na die teater vir postoperatiewe bloeding. Verduidelik
die respiratoriese variasies in polsdruk soos gesien op die diagram.
(6)
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
b)
How is pulse pressure variation calculated?
(1)
b)
Hoe word polsdrukvariasie bereken?
(1)
_________________________________________________________________________
_________________________________________________________________________
c)
What are the limitations to monitoring pulse pressure variation?
(3)
c)
Wat is die beperkinge van polsdrukvariasie-monitering?
(3)
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
[10]
PTO/ Page 6 Question 5
-6Question 5 / Vraag 5
Cholesterol
17OH pregnenolone
Progesterone
Corticosterone
17OH progesterone
Dehydroepiandrosterone
androstenedione
androstenediol
11 deoxycortisol
18OH corticosterone
Aldosterone
a)
a)
(4)
(4)
b)
11
(1)
na
(1)
b)
c)
c)
d)
d)
e)
e)
Which two steroids in the above diagram are glucocorticoids and which two have
mineralocoticoid action?
(2)
Watter twee steroede in bostaande diagram is glukokortikoede en watter twee het
mineralokortikoedaksie?
(2)
Which induction agent can cause adrenal suppression and where does it act?
Watter induksiemiddel kan adrenale onderdrukking veroorsaak en waar vind dit
plaas?
(2)
(1)
(1)
(2)
[10]
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
Question 6 10 / Vraag 6 - 10
-2Question 6 / Vraag 6
a)
a)
Draw the cardiac action potential. Fully annotate your drawing. Indicate which
direction the different electrolytes flow in each cycle. Indicate the different refractory
periods on your drawing. What is the difference between the refractory periods. (10)
Teken die kardiale aksiepotensiaal. Benoem jou skets volledig. Dui aan in watter
rigting die verskillende elektroliete beweeg tydens elke siklus. Dui die verskillende
refraktre periodes aan op u skets. Wat is die verskil tussen die refraktre periods.
(10)
[10]
-3Question 7/ Vraag 7
a)
a)
(2)
(2)
b)
b)
(1)
(1)
c)
c)
(2)
(2)
d)
Describe the process of primary active transport of hydrogen ions during the
formation of hydrochloric acid in the stomach.
(5)
Beskryf die proses van primre aktiewe transport van waterstofione gedurende die
vorming van soutsuur in die maag.
(5)
d)
[10]
-4Question 8/ Vraag 8
List the autonomic receptors found in the following tissues and describe the effect of
sympathetic stimulation on each of them
Lys die outonome reseptore gevind in die volgende weefsel en beskryf die effekte van
simpatiese stimulasie op elk
a)
a)
Heart.
Hart.
(3)
(3)
b)
b)
Arteries.
Arteries.
(2)
(2)
c)
c)
Lung.
Long.
(1)
(1)
d)
d)
Liver.
Lewer.
(3)
(3)
e)
e)
(1)
(1)
[10]
PTO/Page 5 Question 9
-5Question 9 Vraag 9
a)
a)
the
(6)
die
(6)
b)
b)
How does the fetal nicotinic acethylcholine receptor differ from the adult receptor?(1)
Hoe verskil die fetale asetielcholienreseptor van die volwasse reseptor?
(1)
c)
c)
(3)
(3)
[10]
PTO/Page 6 Question 10
-6Question 10/Vraag 10
List the anaesthetically important effects of hypercalcaemia on the following organ systems
Lys die faktore wat die miokardiale suurstofvoorsiening-aanvraagbalans benvloed.
a)
a)
Cardiovascular.
Kardiovaskulr.
(2)
(2)
b)
b)
Renal.
Renaal.
(3)
(3)
c)
c)
Gastrointestinal.
Gastrontestinaal.
(2)
(2)
d)
d)
Musculoskeletal.
Muskuloskeletaal.
(2)
(2)
e)
e)
(1)
(1)
[10]
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
Question 11 15 / Vraag 11 - 15
(1)
(1)
b)
b)
(1)
(1)
c)
c)
(1)
(1)
The colloid osmotic pressure of the plasma falls as blood passes through skeletal
capillaries.
(1)
Die kolloedosmotiese druk van plasma daal wanneer bloed deur skeletale kapillres
beweeg.
(1)
e)
e)
f)
f)
The albumin is responsible for the majority of the colloid osmotic pressure.
(1)
Albumien is verantwoordelik vir die grootste deel van die kolloedosmotiese druk. (1)
g)
g)
The packed cell volume increases as blood passes through systemic capillaries. (1)
Die gepakte selvolume verhoog as bloed deur die sistemies kapillres vloei.
(1)
h)
As blood descends in the vasa recta to the medullary region of the kidney, the colloid
osmotic pressure of the plasma rises.
(1)
Die kolloedosmotiese druk van die plasma styg wanneer bloed afdaal deur die vasa
recta na die medullre deel van die nier.
(1)
h)
i)
i)
j)
j)
(1)
(1)
Non-polar molecules diffuse across the endothelial cell membranes more easily than
polar molecules.
(1)
Nie-polre molekules diffundeer makliker oor die endoteliale membraan dan polre
molekules.
(1)
Small polar molecules pass through the channels between endothelial cells.
Klein polre molekules beweeg deur die kanale tussen endoteliale selle.
(1)
(1)
[10]
-3Question 12 / Vraag 12
Concerning saliva
Betreffende speeksel
a)
a)
(1)
(1)
b)
b)
(1)
(1)
c.
c)
Saliva has a pH of ..
Speeksel pH is.
(1)
(1)
d.
d)
(1)
(1)
(1)
(1)
f)
f)
(1)
(1)
g)
g)
h)
h)
(1)
(1)
i)
i)
(1)
(1)
j)
j)
(1)
(1)
[10]
-5Question 13 / Vraag13
Concerning metabolism
Betreffende metabolisme
a)
a)
A man who has been eating nothing for 6 hours typically has a respiratory quotient
approaching .
(1)
n Man wat niks geet het vir 6-ure nie, het tipies n respiratoriese kofisint van
(1)
b)
b)
c)
c)
(1)
(1)
i)
i)
1g of glucose.
1g glucose.
(1)
(1)
ii)
ii)
1g of fat.
1g vet.
(1)
(1)
iii)
iii)
1g of protein.
1g proteen.
(1)
(1)
d)
d)
(4)
(4)
e)
e)
(1)
(1)
[10]
-6Question 14 / Vraag 14
a)
a)
(3)
(3)
b)
b)
(1)
(1)
c)
c)
d)
d)
(1)
(1)
e)
e)
(1)
(1)
f)
f)
(1)
(1)
[10]
U________________________________
o'________________________________1
c ________________________________1
c ________________________________1
o ________________________________1
1
1
1
1
[10]
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
Question 16 20 / Vraag 16 - 20
-2Question 16 / Vraag 16
Fill in the average normal electrolyte concentrations (in mmol/l)
Gee die normale, gemiddelde elektrolietkonsentrasies (in mmol/l)
In plasma
In plasma
Na+
K+
Ca2+
ClPO4-
[10]
What is Pain?
Wat is pyn?
b)
b)
(2)
(2)
i)
i)
Nociceptive pain.
Nosiseptiewe pyn.
(2)
(2)
ii)
ii)
Neuropathic pain.
Neuropatiese pyn.
(2)
(2)
iii)
iii)
Hyperalgesia
Hiperalgesie.
(2)
(2)
iv)
iv)
Allodynia.
Allodinia.
(2)
(2)
[10]
-4Question 18 / Vraag 18
a)
a)
(2)
(2)
b)
b)
(3)
(3)
c)
c)
(1)
(1)
d)
d)
(2)
(2)
e)
e)
(2)
(2)
[10]
-5Question 19 / Vraag 19
A 24-year-old woman was admitted to a high care unit following a caesarian section. She
was diagnosed with a 'fatty liver of pregnancy' preoperatively. A morphine infusion at 4
mg/hr was started for analgesia. The next day she was noted to be drowsy. She had an
anion gap of 22 and her arterial blood gas revealed the following
n 24-Jarige vrou is opgeneem in hosorg na n keisersnit. Sy is preoperatief gediagnoseer
met lewervervetting van swangerskap. n Morfieninfuus teen 4mg/uur is begin vir
analgesie. Die volgende dag word opgemerk dat sy slaperig is. Sy het n anioongaping van
22 en haar arterile bloedgas wys die volgende
pH 7.12
pCO2 60 mmHg (8 kPa)
pO2 110 mmHg (14.7 kPa)
HCO3- 21 mmol/l
Comment on the
Lewer kommentaar op die
a)
pH
(1)
b)
pCO2
(2)
c)
c)
(5)
Suur-basisversteuring.
(5)
d)
PO2.
(2)
[10]
A 20-year-old healthy man sustains an isolated femur fracture during a biking accident. He
acutely loses 1.5 litres of blood. What is the bodys physiological response to restore
circulating blood volume within 24hours?
(10)
n 20-Jarige, gesonde man, doen n gesoleerde femurfraktuur op in n fietsongeluk. Hy
verloor 1.5 liter bloed. Wat is die liggaam se fisiologiese respons in die volgende 24-uur om
die sirkulerende volume te herstel.
(10)
[10]
FCA(SA) Part I
THE COLLEGES OF MEDICINE OF SOUTH AFRICA
Incorporated Association not for gain
Reg No/Nr 1955/000003/08
Part I Examination for the Fellowship of the
College of Anaesthetists of South Africa
28 August 2012
Pharmacology
Paper 3
(3 hours)
All questions are to be answered. Each question to be answered in a separate book (or books if more than
one is required for the one answer).
Al die vrae moet beantwoord word. Elke vraag moet in n aparte boek (of boeke indien meer as een nodig is
vir n vraag) geskryf word.
Question 1/Vraag 1
a)
Describe the mechanisms of
i)
Normal neuromuscular transmission
ii)
Depolarising neuromuscular blockade
iii)
Non-depolarisingneuromuscular blockade
b)
With reference to scoline apnoea describe its
i)
Pharmacogenetics
ii)
Time course
iii)
Suggested agonist-receptor interactions
iv)
Management
a)
b)
(10)
(6)
(8)
(7)
(6)
(7)
(6)
[50]
Question 2/Vraag 2
a)
Briefly discuss the pharmacokinetics of ketamine.
b)
Write short notes on the mechanism of actions of ketamine.
c)
Describe the potential benefits of S-(+) isomer of ketamine.
d)
Discuss the effects of ketamine on the following organs
i)
Central nervous system
ii)
Respiratory system
iii)
Cardiovascular system
e)
Ketamine enjoys recreational popularity. Discuss.
(10)
(6)
(8)
(7)
(6)
(7)
(6)
[50]
(10)
(10)
(10)
(8)
(4)
(4)
(4)
[50]
-2a)
b)
c)
d)
e)
(10)
(10)
(10)
(8)
(4)
(4)
(4)
[50]
Question 3/Vraag 3
a)
b)
c)
d)
e)
f)
g)
a)
b)
c)
d)
e)
f)
g)
-3Question 4/Vraag 4
a)
b)
c)
d)
e)
f)
g)
Define bioavailability.
(2)
What determines bioavailability of an orally administered drug?
(2)
How is bioavailability calculated for an orally administered drug?
(3)
Discuss the bioavailability of a rectally administered drug (iesuppository). (4)
Define the term volume of distribution.
(2)
List the factors that affect drug distribution within the body.
(5)
Discuss factors affecting drug distribution in the following patient groups. Give
relevant examples, and discuss the relevant clinical implications
i)
an elderly patient
(18)
ii)
a neonate
(8)
iii)
a patient with chronic renal failure
(6)
[50]
a)
b)
c)
Definieer biobeskikbaarheid.
(2)
Wat bepaal die biobeskikbaarheid van n oraaltoegediende middel?
(2)
Hoe word die biobeskikbaarheid van n oraaltoegediende middel bereken?
(3)
Bespreek die biobeskikbaarheid van n rektaaltoegediende middel (setpil). (4)
Definieer die term volume van distribusie.
(2)
Lys die faktore wat middeldistribusie in die liggaam bepaal.
(5)
Bespreek faktore wat middeldistribusie benvloed in die volgende
pasintgroepe. Gee relevante voorbeelde en bespreek die toepaslike kliniese
implikasies
i)
n bejaarde pasint
(18)
ii)
n neonaat
(8)
iii)
n pasint met chroniese nierversaking
(6)
[50]
d)
e)
f)
g)
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
-2Question 1/Vraag 1
Discuss the possible advantages and disadvantages of using pethidine in neuraxial blockade, in
terms of
Bespreek die moontlike voordele en nadele van die gebruik van petidien in neuraksiale blokkade in
terme van
a)
(3)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
______________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
Its metabolites.
Die metaboliete.
(3)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________[10]
PTO/Page 3 Question 2...
-3Question 2/Vraag 2
Write short notes on the perioperative use of anticholinergic drugs in
Skryf kort notas oor die perioperatiewe gebruik van anticholinerge middels met
a)
Premedication.
Premedikasie.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
Prophylaxis.
Profilakse.
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
Emergency management.
Noodhantering.
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________ [10]
-4Question 3/Vraag 3
Briefly discuss the factors that influence local anaesthetic
Bespreek kortliks die faktore wat bepalend is by lokaalverdowers se
a)
Onset times.
Aanvangstyd van werking.
(6)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
Offset times.
Werkingsduur.
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
__________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________ [10]
-5Question 4/Vraag 4
Describe briefly the structure-function relationships of the volatile anaesthetic molecules as a group
with regard to their
Bespreek kortliks die struktuur-funksieverwantskap van narkosedampmolekules as n groep met
betrekking tot hul
a)
Pharmacological efficacy.
Farmakologiese effektiwiteit.
(6)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
Safety.
Veiligheid.
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________[10]
-6Question 5/Vraag 5
Write short notes on the position of nitrous oxide in modern anaesthetic practice, bearing in mind its
Skryf kort notas oor die posisie van laggas in moderne narkosepraktyk met betrekking tot die
a)
Physical properties.
Fisiese eienskappe.
(3)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
Chemical properties.
Chemiese eieskappe.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
Pharmacological properties.
Farmakologiese eienskappe.
(5)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________[10]
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
Question 6 10 / Vraag 6 - 10
-2Question 6/Vraag 6
Discuss the pharmacological actions of magnesium sulphate in terms of
Bespreek die farmakologiese werking van magnesiumsulfaat in terme van
a)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
(8)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________[10]
-3Question 7 /Vraag 7
With respect to methylene blue describe its
Met betrekking tot metileenblou beskryf die
a)
Mechanism of action.
Werkingsmeganisme.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
Physicochemical properties.
Fisies-chemiese eieskappe.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
Surgical uses.
Chirurgiese aspekte.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
d)
Toxicity.
Toksisiteit.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
e)
Absolute contraindications.
Absolute kontra-indikasies.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________[10]
PTO/Page 4 Question 8...
-4Question 8/Vraag 8
List the antidotes to the following drugs
Lys die teenmiddels vir die volgende middels
a)
Methanol.
Metanol.
_______________________________________________________________________________
_______________________________________________________________________________
b)
Cyanide.
Sianied.
_______________________________________________________________________________
_______________________________________________________________________________
c)
_______________________________________________________________________________
_______________________________________________________________________________
d)
Sulfonylurea-induced hypoglycaemia.
Sulfonielurea-genduseerde hipoglukemie.
_______________________________________________________________________________
_______________________________________________________________________________
e)
_______________________________________________________________________________
_______________________________________________________________________________
f)
Acetaminophen.
Parasetamol.
_______________________________________________________________________________
_______________________________________________________________________________
g)
Carbon monoxide.
Koolstofmonoksied.
_______________________________________________________________________________
_______________________________________________________________________________
h)
Iron.
Yster.
_______________________________________________________________________________
_______________________________________________________________________________
i)
Isoniazid.
Isoniasied.
_______________________________________________________________________________
_______________________________________________________________________________
j)
Methaemoglobinaemia.
Methemoglobienemie.
_______________________________________________________________________________
_______________________________________________________________________________
[10]
-5Question 9/Vraag 9
Regarding digoxin
Betrefende digoksien
a)
(5)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
(5)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
-6Question 10/Vraag 10
Discuss diazepam under the following headings
Bespreek diasepam onder die volgende hoofde
a)
Physicochemical properties.
Fisies-chemiese eienskappe.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
Absorption.
Absorpsie.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
Metabolism.
Metabolisme.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
d)
Drug interactions.
Middelinteraksies.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
e)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
Question 11 15 / Vraag 11 - 15
-2Question 11/Vraag 11
a)
i)
Heparin.
Heparien.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
ii)
Warfarin.
Warfarien.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
iii) Dabigatran.
Dabigatran.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
iv) Rivaroxiban.
Rivaroxiban.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
b)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
___________________________________________________________________________ [10]
PTO/Page 3 Question 12...
-3Question 12/Vraag 12
Briefly discuss oxytocin under the following headings
Bespreek oksitosien kortliks onder die volgende hoofde
a)
Chemical constitution.
Chemiese samestelling.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
b)
Clinical use.
Kliniese gebruik.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
Side effects.
Newe-effekte.
(5)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
d)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
____________________________________________________________________________[10]
-4Question 13/Vraag 13
List 5 groups of drugs effective in prevention and/or treatment of PONV, and briefly explain the
mechanism of action of each
Lys 5 groepe van middels wat effektief is in die vookoming en behandeling van PONB en
verduikelik kortliks die meganisme van elk
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
-5Question14/Vraag 14
a)
(3)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
List the side effects that may manifest in a patient taking amiodarone.
Lys die newe-effekte wat manifesteer in n pasint wat amiodaroon gebruik.
(7)
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
____________________________________________________________________[10]
-6-
Question 15/Vraag 15
Briefly explain how the interaction of the following drugs with specific receptors cause their clinical
effect
Verduidelik kortliks hoe die volgende middels se interaksie met spesifieke reseptore hul kliniese
effek bepaal
a)
Propofol.
Propofol.
(3)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
Ketamine.
Ketamien.
(3)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
Midazolam.
Midasolam.
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
Question 16 20 / Vraag 16 - 20
-2Question 16/Vraag 16
a)
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
List three major side effects of cyclophosphamide treatment that are relevant to anaesthesia.
(3X3)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
-3-
Question 17/Vraag 17
What are the effects of 1 MAC isoflurane on
Wat is die effekte van 1 MAK isofluraan op
a)
Blood pressure.
Bloeddruk.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
Cardiac output.
Kardiale uitwerp.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
d)
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
e)
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
f)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
g)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
PTO/Page 4 Question 18
-4Question 18 /Vraag 18
Regarding nonsteroidal anti-inflammatory drugs: Rofecoxib (Vioxx) was withdrawn from the market
in 2004 following reports of an increased risk of adverse cardiovascular events with chronic use.
Betreffende nie-steroed anti-inflammatoriese middels: Rofecoxib (Vioxx) is onttrek van die mark in
2004 na verslae van n verhoogde risiko vir kardiovaskulre insidente met chroniese gebruik
a)
(5)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
(3)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
PTO/Page 5 Question 19...
-5Question 19 /Vraag 19
Regarding hypertonic saline
Betreffende hipertoniese saline
a)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
How does this mechanism of action differ from that of commonly used colloids (e.g. a
vir volumeverruiming?
(1)
_______________________________________________________________________________
_______________________________________________________________________________
d)
How many mmol/l of sodium ions are present in 3% hypertonic saline? Show your calculation.
Hoeveel mmol/l natriumione is in 3% hipertoniese saline? Wys u berekeninge.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
e)
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
f)
What is the initial dose of hypertonic saline used for small volume resuscitation?
Wat is die aanvangsdosering van hipertoniese saline vir kleinvolume-resussitasie?
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
g)
Why might hypertonic saline offer advantages over an isotonic crystalloid (e.g. Ringers
resussitasie?
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
-6Question 20 /Vraag 20
a)
i)
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
ii)
A nonselective blocker.
n Non-selektiewe -blokker.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
__________________
iii) A cardioselective blocker.
n Kardioselektiewe -blokker.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
d)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
e)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]
FCA(SA) Part I
THE COLLEGES OF MEDICINE OF SOUTH AFRICA
Incorporated Association not for gain
Reg No/Nr 1955/000003/08
Part I Examination for the Fellowship of the
College of Anaesthetists of South Africa
29 August 2012
Physics
Paper 5
(3 hours)
All questions are to be answered. Each question to be answered in a separate book (or books if more than
one is required for the one answer).
Al die vrae moet beantwoord word. Elke vraag moet in n aparte boek (of boeke indien meer as een nodig is
vir n vraag) geskryf word.
Question 1/Vraag 1
a)
Classify LASERs according to the International Electrotechnical Commission
(IEC) risk classification schema.
(5)
b)
Tabulate the different types of LASER used in clinical practice. Make mention
of the application and the specific characteristics of the individual LASERs.
(10)
c)
Write short notes on the production of LASER. Use diagrams to explain your
answer if necessary.
(10)
d)
Explain flammability limits and why adding nitrous oxide to a mixture
increases flammability.
(5)
e)
Write short notes on the prevention of fires in theatre.
(10)
f)
Write short notes on the management of an airway fire.
(5)
g)
Classify fire extinguishers and give examples of fires for which they can be
used.
(5)
[50]
a)
b)
c)
d)
e)
f)
g)
PTO/Page 2 Question 2
-2Question 2/Vraag 2
a)
b)
c)
d)
e)
f)
g)
(5)
-3b)
Verduidelik deur middel van n benoemde diagram hoe die volgende inligting
van n arterile drukgolf verkry kan word
(10)
i)
Miokardiale kontraktiliteit
ii)
Slagvolume
iii)
Sistemiese vaskulre weerstand
iv)
Gemiddelde arterile druk
v)
Status van die sirkulerende volume
c)
Gee kort verduidelikings vir die volgende konsepte
(6)
i)
Fundamentele frekwensie
ii)
Natuurlike frekwensie
iii)
Dempingskofisint
d)
Lys die faktore wat die natuurlike frekwensie van n arterile lyn
moniteringsisteem benvloed.
(5)
e)
Gee n formule om die naturlike frekwensie te bereken.
(2)
f)
Wat is die aanvaarbare natuurlike frekwensie van n arterile lynsisteem. (2)
g)
Die volgende grafiek is n vinnige spoel-piektoets van n arterile lyn
moniteringsisteem
Gebruik die grafiek en bereken die volgende:
i)
Natuurlike frekwensie
(5)
ii)
Amplitudeverhouding
(5)
h)
Beskryf met behulp van benoemde diagramme die verskille wat waargeneem
sal
word in die arterile drukkurwes wat gelyktydig geneem word van die radialeen
dorsalis pedis arterile kateters.
(10)
[50]
Question 3/Vraag 3
a)
List ten (10) causes of operating theatre pollution or contamination with
gases.
(10)
b)
What is the recommended exposure limit or trace level for nitrous oxide and
halogenated anaesthetic agents?
(2)
c)
Classify scavenging systems.
(3)
d)
Draw and label the component systems of standard scavenging techniques
and briefly describe the function of each system and necessary
specifications.
(20)
e)
What are the potential occupational hazards of operating theatre pollution? (5)
f)
Regarding operating theatre ventilation
i)
What is efficient ventilation?
(1)
ii)
Briefly discuss the effects of other environmental factors on infection
control.
(9)
[50]
a)
b)
c)
d)
e)
f)
Lys tien (10) oorsake van teaterbesoedeling of kontaminasie met gasse. (10)
Wat is die voorgestelde blootstellingslimiet of spoorvlakke vir laggas en
gehalogeneerde narkosemiddels.
(2)
Klassifiseer opruimingsisteme.
(3)
Teken en benoem die komponentsisteme van standaard opruimingtegnieke
en beskryf kortliks die funksie van elke sisteem asook die nodige
spesifikasies.
(20)
Wat is die potensile beroepsgevare van teaterbesoedling?
(5)
Betreffende teaterventilasie
i)
Wat is effektiewe ventilasie?
(1)
ii)
(9)
[50]
PTO/Page 4Question 4
-4Question 4 /Vraag 4
The lack of temperature management in theatre leads to morbidity and mortality.
Discuss temperature management in theatre under the following headings
a)
Different methods of measuring body temperature in theatre (electrical vs.
non- electrical)
(5)
b)
Heat loss in theatre, physical principles.
(15)
c)
Different ways of conserving body temperature in theatre(physical
principles).
(20)
d)
Difference between core and shell temperature.
(4)
e)
Thermal burns in theatre and the causes.
(6)
[50]
Swak temperatuurbeheer in teater lei tot morbiditeit en mortaliteit.
Bespreek temperatuurbeheer in die teater onder die volgende hoofde
a)
Verskillende metodes om liggaamstemperatuur in teater te meet (elektries
teenoor non-elektries).
(5)
b)
Hitteverlies in teater, fisiese beginsels.
(15)
c)
Verskillende metodes om liggaamstemperatuur te behou in teater (fisiese
beginsels).
(20)
d)
Verskil tussen kern- en oppervlakstemperatuur
(4)
e)
Termiese brandwonde in teater en die oorsake daarvan.
(6)
[50]
FCA(SA) Part I
(2 hours)
Candidate Number:....................................................
-2Question 1/Vraag 1
With respect to the Systme International d'units (SI) units, state the derived SI unit and the SI
base units for
Met betrekking tot die Systme International d'units (SI) eenhede, gee die afgeleide SI-eenhede
asook die basiseenhede vir
a)
Work.
Arbeid.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
Electric Charge.
Elektriese lading.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
-3Question 2/Vraag 2
Regarding Entonox (50:50 nitrous oxide/oxygen)
Betreffende Entenox (50:50 laggas/suurstof)
a)
(2)
-4d)
You are asked to transport a ventilated patient. Given an oxygen flow rate of 8L/min from a
cylinder
with an empty volume of 5L with a pressure gauge reading of 5000 kPa, calculate
how many minutes
of gas supply are present in the cylinder. Show all calculations.
U moet n geventileerde pasint vervoer. Bereken hoeveel minute se gasvloei oor is vanuit
die silinder, gegewe die suurstofvloeitempo van 8L/min, n silinder met n le volume van 5L en
n drukmeter wat 5000 kPa lees. Wys u berekening.
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
e)
-5Question 3/Vraag 3
a)
List potential complications which may arise from the use of a trans-oesophageal echo device.
Lys die potensile komplikasies wat mag voorkom met die gebruik van n transesofageale
eggo-apparaat.
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
For each listed Doppler mode give 2 examples of their clinical application.
Gee 2 voorbeelde vir elke Doppler-modus en die kliniese toepassing.
i)
Pulse Wave Doppler.
Pulse Wave Doppler.
(1)
_______________________________________________________________________________
_______________________________________________________________________________
ii)
-6-
Question 4/Vraag 4
A Coagulation monitoring device produces the output shown below
n Stollingsmoniteringsapparaat gee die resultaat hieronder
a)
What is indicated by A and what information can be obtained from its value?
Wat word aangedui deur A en watter inligting kan verkry word uit hierdie waarde?
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
What is indicated by B and what information can be obtained from its value?
Wat word aangedui deur B en watter inligting kan verkry word uit hierdie waarde?
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
using
Briefly describe the physical principles and function of the device which produces this graph,
diagrams if required.
Beskryf kortliks, met behulp van diagramme as nodig, die fisiese eienskappe en funksionering
(4)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
PTO/Page 7 Question 4d)...
-7-
d)
Fibrinolysis.
(1)
Fibrinolise.
ii)
Dilutional coagulopathy.
Verdunningskoagulopatie.
(1)
[10]
-8Question 5/Vraag 5
Oxygen concentrators are typically used in situations where Vacuum Insulated Evaporator (VIE) or
bottled oxygen is prohibitively expensive or impractical
Suurstofkonsentreerders word gebruik in situasies waar die Vacuum Insulated Evaporator (VIE) of
gebottelde suurstof te duur of onprakties is
a)
(1)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
b)
(7)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
c)
(2)
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
[10]